T. Spelman Et Al. , "Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity," Multiple Sclerosis and Related Disorders , vol.70, 2023
Spelman, T. Et Al. 2023. Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity. Multiple Sclerosis and Related Disorders , vol.70 .
Spelman, T., Horakova, D., ÖZAKBAŞ, S., Alroughani, R., Onofrj, M., Kalincik, T., ... Prat, A.(2023). Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity. Multiple Sclerosis and Related Disorders , vol.70.
Spelman, Tim Et Al. "Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity," Multiple Sclerosis and Related Disorders , vol.70, 2023
Spelman, Tim Et Al. "Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity." Multiple Sclerosis and Related Disorders , vol.70, 2023
Spelman, T. Et Al. (2023) . "Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity." Multiple Sclerosis and Related Disorders , vol.70.
@article{article, author={Tim Spelman Et Al. }, title={Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity}, journal={Multiple Sclerosis and Related Disorders}, year=2023}